Z19.2
Hormone resistant malignancy status
Clinical Classification Guidelines
Inclusion Terms
- Castrate resistant prostate malignancy status
Medical Intelligence & Overview
Hormone-resistant malignancy refers to a type of cancer that no longer responds to hormone therapy designed to stop its growth. In particular, this term is often associated with prostate cancer, where the disease continues to progress despite hormone treatment. Recognizing this phase is crucial for guiding future treatment options and managing expectations. The ICD-10 code Z19.2 specifically identifies cases where the cancer is resistant to hormonal therapy, indicating a more advanced or aggressive disease course.
Causes & Symptoms
Clinical Causes: Development of cancer cells that do not require hormones to grow Mutation or genetic changes in cancer cells that confer hormone independence Prolonged exposure to hormone therapy leading to resistance Evolution of the tumor over time, making it less susceptible to initial treatments
Key Symptoms: Progressive worsening of cancer-related symptoms despite hormone therapy Increased urinary difficulties in prostate cancer, such as difficulty urinating or weak stream Bone pain if cancer has spread to bones Unexplained weight loss Fatigue and general decline in health status
Diagnostic & Treatment
Diagnosis Path: Diagnosing hormone-resistant malignancy involves a combination of clinical evaluation and diagnostic tests. Typically, healthcare providers monitor the patient's response to hormone therapy through imaging, blood tests such as PSA levels in prostate cancer, and biopsies if necessary. When indicators show that the cancer is progressing despite hormone treatment, and other causes are ruled out, a diagnosis of hormone-resistant malignancy is made. Specific criteria and markers may vary depending on the type of cancer and individual circumstances.
Treatment Protocols: Management of hormone-resistant malignancy often involves alternative treatment strategies beyond hormone therapy. These may include targeted therapies, chemotherapy, immunotherapy, or radiation therapy. Clinical trials exploring new treatments are also an option for suitable patients. Close monitoring is essential to assess treatment response and adjust plans accordingly. Supportive care becomes increasingly important to manage symptoms and maintain quality of life during ongoing treatment.
Clinical Advice & FAQs
Billing Guidance
Is Z19.2 a billable ICD-10 code?
Yes, Z19.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z19.2?
Clinical documentation must specify the nature of Hormone resistant malignancy status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference